ArticleHealth science reports2025
Outcomes and Adverse Events of WHO Shorter Regimen in the Treatment of Multi-Drug Resistant Tuberculosis in Bhutan: A Longitudinal Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictors of unsuccessful tuberculosis treatment outcome in Bhutan: A retrospective study using comprehensive national tuberculosis surveillance data.Scientific reports · 2026Article
- Outcomes and Adverse Events of WHO Shorter Regimen in the Treatment of Multi-Drug Resistant Tuberculosis in Bhutan: A Longitudinal Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Bhutan first introduced the Shorter Regimen, consisting of a combination of Amikacin, Clofazamine, Ethionamide, Ethambutol, high dose Isoniazid, Moxifloxacin and Pyrazinamide, for the treatment of rifampicin or multidrug resistant tuberculosis (RR/MDR-TB) in 2018. This study describes the outcome, time to sputum conversion and adverse events of treatment among MDR-TB patients treated with the Shorter Regimen in Bhutan. Methods: This was a longitudinal study among patients with RR/MDR-TB who were treated with the Shorten Regimen between 2018 and 2020. Throughout the treatment period, sputum smear, culture, and blood investigations were monitored. Results: There were 52 patients who received the shorter regimen for MDR-TB. Forty-seven patients (90%) had pulmonary TB (PTB) and five (10%) had extra-pulmonary TB (EPTB). Forty-one patients (79%) had confirmed MDR-TB and 11 (21%) had RR-TB. MDR-TB was detected in new cases in 35 patients (69%), while 11 (22%) were cases of TB relapse and five (10%) were cases of treatment failure. There were 40 patients (86%) who achieved sputum smear conversion by the end of 4 months while all patients became culture negative by the end of 3 months. All patients achieved culture conversion by the end of 3 months. The treatment success rate was 94% and there were no deaths. The common side effects were nausea, vomiting, arthralgia, dizziness, sleep disturbances, depressed mood and skin rash. QTc prolongations were observed in six patients, for which five patients needed dose modification of Moxifloxacin. Five patients had hepatitis, and two needed dose modification. Two patients were switched to the longer regimen due to amikacin-induced profound hearing loss and nephrotoxicity. Conclusions: The treatment success rate of MDR-TB was high, with high sputum and culture conversion rates. Adequate monitoring of side effects is important in providing timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.